Fierce Pharma
MARCH 21, 2024
Drug developers often try to spot tidbits of positive information from a failed clinical trial. | Drug developers often try to spot tidbits of positive information from a failed clinical trial. But Roche is doing the opposite for its positive Enspryng study in the competitive autoimmune disorder of myasthenia gravis.
MedCity News
MARCH 21, 2024
Through a new strategic alliance, Prime Therapeutics will be the only PBM — aside from Capital Rx — to use Capital Rx’s JUDI platform.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 21, 2024
Amid congressional scrutiny on U.S. | The drugmaker's commitment will start by January 1, 2025, and follows similar moves by peers Boehringer Ingelheim and AstraZeneca. Before the pledges, the companies—and Teva—caught Senate heat over high U.S. inhaler prices.
MedCity News
MARCH 21, 2024
Many people don’t take well to the term “healthcare consumer,” or have expressed that they prefer to be referred to as a patient rather than a consumer. But in the U.S., it’s a plain fact that people have choices when it comes to their healthcare. In this piece, three health system executives give their take on why “patient” and “consumer” are often one in the same — and why hospitals need to be mindful of this.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
MARCH 21, 2024
Three large pharma companies plan to expand their manufacturing footprints. Kyowa Kirin’s $4.25 million gene therapy set a new world pricing record. | Three large pharma companies plan to expand their manufacturing footprints. Kyowa Kirin’s $4.25 million gene therapy set a new world pricing record. BeiGene’s PD-1 inhibitor finally crossed the FDA finish line after a 20-month delay.
MedCity News
MARCH 21, 2024
Mirador Therapeutics applies machine learning to human data to discover new immunology and inflammation drugs. The startup’s management includes several from the executive team of Prometheus Biosciences, an immunology biotech bought by Merck last year.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTimes
MARCH 21, 2024
The globally fast-growing progressive neurological condition affects around 153,000 people in the UK
Fierce Pharma
MARCH 21, 2024
Merck’s attempt to use Lynparza to boost Keytruda in metastatic non-small cell lung cancer has come up short with a second pivotal trial failure. | Merck’s attempt to use Lynparza to boost Keytruda in metastatic non-small cell lung cancer has come up short with a second pivotal trial failure.
pharmaphorum
MARCH 21, 2024
Novartis-supported multiple research project will use Seqster's data-sharing platform to support R&D and evidence-based care
Fierce Pharma
MARCH 21, 2024
In his final year as CEO at Bristol Myers Squibb, Giovanni Caforio took a slight dip in pay to $19.7 million, down from the $20.1 million he collected in 2022, according to the company’s | In his final year as CEO at Bristol Myers Squibb, Giovanni Caforio took a slight dip in pay to $19.7 million, down from the $20.1 million he collected in 2022.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
MARCH 21, 2024
Surgeon General Vivek Murthy recently described mental health as “the defining public health crisis of our time.” No crisis can be tackled without the proper tools. As the burden of mental and behavioral illness continues to rise, now is the time to invest in the future well-being of our population.
pharmaphorum
MARCH 21, 2024
Clasp Therapeutics has burst onto the T-cell engager (TCE) scene with $150 million in funding for a platform that aims to improve the safety of the class, which is currently gaining traction in cancer immunotherapy.
European Pharmaceutical Review
MARCH 21, 2024
Can you tell us a bit about yourself and your role at Pfizer? I’m a pharmacist with an MBA and PhD. My PhD thesis is about considerations in the production and purchasing of drugs. I joined Pfizer in January 2023 as a health access specialist, after working at Clalit Health Services in Israel for almost 20 years. At Clalit, which is the second largest healthcare provider in the world, I worked in several management positions and gained a broad understanding of the needs and constraints of a heal
pharmaphorum
MARCH 21, 2024
A partnership between Eisai and Lifenet that aims to improve insurance cover for people with early dementia has generated its first policy, part of an effort by the pharma group to develop an ‘ecosystem’ to support patients.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
MARCH 21, 2024
Bionomics plans to meet with the FDA following positive topline data from the Phase IIb ATTUNE trial of the post-traumatic stress disorder (PTSD) drug BNC210.
pharmaphorum
MARCH 21, 2024
Surgeons in the US have carried out the world’s first transplant of a pig kidney into a human, a feat made possible by genetic modification of the organ and an experimental immunosuppressant drug regimen to prevent rejection. The recipient, 62-year-old Richard Slayman of Weymouth in Massachusetts, had end-stage renal disease and was dependent on dialysis.
Pharmaceutical Technology
MARCH 21, 2024
Merck KGaA has announced an investment of over €300m ($326.1m) to establish a new bioprocessing production centre in Daejeon, South Korea.
European Pharmaceutical Review
MARCH 21, 2024
A new £17.9 million strategic initiative is set to support UK advanced therapy medicinal product (ATMP) clinical trials, and help the region maintain its position as a leader in clinical research. An additional four years of funding for the Advanced Therapy Treatment Centre ( ATTC ) network is available through this programme. Collaborators include the National Institute for Health and Care Research (NIHR), Innovate UK, the ATTC network and the Cell and Gene Therapy Catapult (CGT Catapult).
Pharmaceutical Commerce
MARCH 21, 2024
A multiple myeloma survivor shares his story, including how patient assistance made a positive impact.
Pharmaceutical Technology
MARCH 21, 2024
The EC has approved BMS' Abecma (idecabtagene vicleucel; ide-cel) to treat adults with relapsed and refractory multiple myeloma (RRMM).
European Pharmaceutical Review
MARCH 21, 2024
Biopharma and bioprocessing experts have proposed an approach that uses a two-tiered control strategy for rapid bioburden testing, that can beneficially, “leverage faster detection times”. It comprises of a “fast (but possibly less sensitive) test” for process monitoring which then initiates “action for a second, longer duration test which is used to confirm and quantify the presence of bioburden and identify the [ microbial ] organism.
Pharmaceutical Technology
MARCH 21, 2024
Biotech executives discuss why developing gene therapies for central nervous system disorders remains difficult at a recent conference.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaVoice
MARCH 21, 2024
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
Pharmaceutical Technology
MARCH 21, 2024
Capstan Therapeutics has secured $175m Series B financing to advance its lead in vivo CAR-T candidate, CPTX2309, for autoimmune disorders.
PharmaTech
MARCH 21, 2024
More synthetic opioids have been placed under the strictest controls in the United Kingdom.
PharmaTimes
MARCH 21, 2024
The bacterial infection transmitted by ticks affects nearly half a million people in the US every year
MedCity News
MARCH 21, 2024
In order to understand the current state of the healthcare system it is essential to have comprehensive sources of real-world and integrated data linked with data from across the healthcare ecosystem.
Pharmaceutical Technology
MARCH 21, 2024
Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.
pharmaphorum
MARCH 21, 2024
Bayer cuts its pharma management, with Sebastian Guth promoted to chief operating officer and Christine Roth heading a new commercial unit
Pharmacy Times
MARCH 21, 2024
The data comes from 2 phase 4 trials, ENABLE and EMPOWER, which evaluated lanadelumab and the outcomes of treatment in adolescents with hereditary angioedema.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
298 
Let's personalize your content